Deliver Your News to the World

Active Biotech to Present at the Rodman & Renshaw


WEBWIRE –

Lund, Sweden - 12 May 2006 - Active Biotech (Stockholm: ACTI.ST) management is scheduled to present at the Rodman & Renshaw Annual Global Healthcare Conference next week on Tuesday, May 16 at 2:40 pm CEST (8:40 am EDT) in Monaco. During the presentation, management will provide an update on the Active Biotech development program as well as a description of the recently signed partnership agreement with Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) regarding the I-3D project.



The presentation will include an update on the following drugs: laquinimod, the company’s oral MS drug for which it is in partnership with Teva Pharmaceutical Industries Ltd.; ANYARA, Active Biotech’s novel concept for the treatment of lung and renal cancer; and other key projects in clinical development, such as TASQ, for prostate cancer; 57-57, for Lupus (SLE) and RhuDex® (licensed to Avidex Ltd.) for rheumatoid arthritis. The presentation will also cover the pre-clinical I-3D project in co-development with Chelsea Therapeutics.

The Active Biotech audio and slide presentation will be web cast live on May 16, at 2:40 pm CEST / 8:40 am EDT. A replay will be available approximately one hour following the presentation and archived on the company’s web site. To access the live and replay presentations, visit the Active Biotech web site - www.activebiotech.com.

About Active Biotech
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects comprise the three orally administered compounds in clinical development, TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA as well as the I-3D project in pre-clinical co-development with Chelsea Therapeutics.

WebWireID14042





This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.